|Bid||3.7700 x 900|
|Ask||3.9500 x 1800|
|Day's range||3.6700 - 3.9500|
|52-week range||3.6700 - 10.9300|
|Beta (5Y monthly)||2.18|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.29|
Dogecoin (CRYPTO: DOGE), in many ways, is at the epicenter of the cryptocurrency craze. In fact, Dogecoin's price has fallen by more than 58% from its recent highs, implying that the rampant enthusiasm that drove the coin's price through the roof earlier this year may be waning, perhaps for good. The good news is that there are a handful of biotech penny stocks (equities with a sub-$5 share price) capable of delivering jaw-dropping returns for risk-tolerant investors.
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Adaptimmune Therapeutics (NASDAQ: ADAP), a biotech company active in the hot immunotherapy segment, was a high-temperature stock on Thursday. In advance of a June industry congress, Adaptimmune unveiled the results of its SPEARHEAD-1 study. This was undertaken to gauge the efficacy of its afamitresgene autoleucel, or afami-cel, to treat synovial sarcoma (cancer of soft tissue such as muscles or ligaments) and myxoid/round cell liposarcoma (MRCLS; a cancer of the cells that store fat).